GDRB.BU

GDRB.BU maintains a strong liquidity position, with a current ratio of 4.37 and cash and equivalents amounting to HUF 211.68 billion, which is well above the industry median. The company's debt-to-equity ratio is 0.05, indicating a conservative capital structure with minimal leverage. This low debt level supports financial flexibility and reduces exposure to interest rate volatility. The company's profitability is robust, with a return on equity (ROE) of 16.61% and a return on assets (ROA) of 13.68%, both exceeding the industry median for pharmaceutical firms. These metrics suggest efficient use of equity and assets to generate returns. Gross profit of HUF 62.99 billion and operating income of HUF 29.31 billion further reinforce the company's strong margins. GDRB.BU's revenue is concentrated in its domestic market, with no disclosed international operations in the latest financial data. This geographic concentration may limit growth opportunities but also reduces exposure to foreign exchange and regulatory risks. The company's revenue of HUF 92.90 billion reflects a stable business model, though international expansion could be a strategic growth lever. Looking ahead, the company is projected to maintain a steady growth trajectory, with no significant negative outlook indicators. Free cash flow of HUF 12.28 billion and operating cash flow of HUF 27.64 billion support reinvestment and shareholder returns. The absence of dilution risk and low liquidity concerns further supports a stable financial outlook. Risk factors for GDRB.BU include regulatory changes in the pharmaceutical sector and potential pricing pressures from government reimbursement policies. However, the company's strong cash position and low debt levels mitigate these risks. No immediate dilution or liquidity flags were detected in the latest filings. Recent events include the publication of the latest financial report, which confirmed the company's strong cash position and profitability. No material adverse events or regulatory actions were disclosed in the most recent filings.